Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Call Transcript

Emily Leproust: And it’s a great question. So yes, we are delaying the on-premise technology development and we mostly, we 100% needed asthmatic synergies for that on-premise, we had said to that we could use asthmatic in house and that will have the choice of chemical and asthmatic. And in the current decisive actions that we’ve made, we have not touched the asthmatic program. We think even though the first product for the test storage, it’s going to be an in-house machine. Right now we saw that there is some potential advantage for us to use the asthmatic program that we have been pursuing and so we have optionality. The first product could be asthmatic or chemicals, we’re pursuing both, but I’m optimistic that we may leverage the asthmatic technology for that first data storage launch.

Operator: Thank you. And I will now turn the call back over to Emily Leproust for any closing remarks.

Emily Leproust: Thank you very much for joining us today and appreciate getting a little bit beyond schedule. We look forward to seeing some of you at Goldman Sachs, William Blair and Scotiabank in the next few months ahead. Thank you.

Operator: Ladies and gentlemen, that does end our conference for today. Thank you for your participation. You may now disconnect.